


# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1

Note: POLARIS-1 published in tandem with POLARIS-4

# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Study Features

- **Design:** Randomized, placebo-controlled, phase 3 trial to evaluate the efficacy of a fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir for 12 weeks in NS5A-inhibitor-experienced patients with GT 1-6 chronic HCV infection
- **Setting:** 108 sites in United States, Canada, New Zealand, Australia, France, Germany, and United Kingdom
- **Entry Criteria**
  - Age  $\geq 18$  years
  - Chronic HCV (any genotype)
  - HCV RNA  $\geq 10,000$  IU/mL at screening
  - Prior treatment failure with DAA that contained NS5A inhibitor
  - Patients with compensated cirrhosis allowed
- **Primary End Point:** SVR12

# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Study Design



- GT 1 patients randomized 2:1 ratio (active:placebo). Stratified by presence of cirrhosis (target  $\geq 30\%$ )
- Genotypes 2-6 were assigned to active arm (and not randomized)
- Placebo recipients were eligible for deferred treatment with sofosbuvir-velpatasvir-voxilaprevir

## Drug Dosing


Sofosbuvir-Velpatasvir-Voxilaprevir (400/100/100 mg): fixed dose combination; one pill once daily

Placebo: one pill once daily

# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Baseline Characteristics

Baseline Characteristics	SOF-VEL-VOX (n = 263)	Placebo (n = 152)
Age, mean (range)	58 (27-84)	59 (29-80)
Male, n (%)	200 (76)	121 (80)
White, n (%)	211 (80)	124 (82)
HCV genotype—no. (%)		
1	150 (57)	150 (99)
1a	101 (38)	117 (77)
1b	45 (17)	31 (20)
1 (other)	4 (2)	2 (1)
2	5 (2)	0
3	78 (30)	0
4	22 (8)	0
5	1 (<1)	0
6	6 (2)	2 (1)
Mean HCV RNA, log <sub>10</sub> IU/mL (range)	6.3 ± 0.7	6.3 ± 0.6
IL28B CC, n (%)	47 (18)	27 (18)
Cirrhosis, n (%)	121 (46)	51 (34)


# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Prior NS5A Treatment



# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6


## POLARIS-1: Results

### POLARIS-1: SVR12 Results by Genotype




# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Results

## POLARIS-1: SVR 12 by Cirrhosis Status



# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Results

## POLARIS-1: SVR 12 by Cirrhosis Status






# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6

## POLARIS-1: Results

### POLARIS-1: SVR12 by Baseline Resistance-Associated Substitutions (RAS)



83% of patients had baseline resistance-associated substitutions (RASs); 79% had NS5A RASs.  
None who relapsed had treatment-emergent RASs.

# Sofosbuvir-Velpatasvir-Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1: Adverse Events

Adverse Event (AE)	SOF-VEL-VOX (n = 263)	Placebo (n = 152)
Discontinuation due to AE—no. (%)	1 (<1) <sup>§</sup>	3 (2)
Serious AEs—no. (%)	5 (2)	7 (5)
Deaths—no.	0	0
Any AE in ≥5% of patients—no. (%)		
Headache	66 (25)	26 (17)
Fatigue	56 (21)	30 (20)
Diarrhea	47 (18)	19 (12)
Nausea	37 (14)	12 (8)
Laboratory AEs Grade 3 or Above—no. (%)	18 (6.9%)	22 (14.5%)

<sup>§</sup>One participant in active arm discontinued due to angioedema attributed to ramipril.

# Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-1 and POLARIS-4: Conclusions

**Conclusions:** “Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed.”

# Acknowledgments

**Hepatitis C Online** is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



*The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.*